Ligand Pharmaceuticals Announces Worldwide License Agreement With ONO PHARMACEUTICAL CO., LTD.

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its worldwide OmniAb platform license agreement with ONO PHARMACEUTICAL CO., LTD. Under the license, ONO will be able to use the OmniRat, OmniMouse and OmniFlic platforms for antibody development.

ONO PHARMACEUTICALS is a research and development oriented pharmaceutical company that develops innovative medicines. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.